Business Context and Reporting Period
Company: AtriCure, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 14, 2010
Event: The company announced the receipt of clearance from the U.S. Food and Drug Administration (FDA) for its AtriClip Gillinov-Cosgrove Left Atrial Appendage Exclusion system.
Key Financial Metrics
This filing is a current report regarding a regulatory event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the regulatory approval of a new medical device system. No financial performance changes or comparisons to prior periods are included in this document.
Outlook, Risks, and Management Commentary
Management Commentary: The filing incorporates by reference a press release (Exhibit 99.1) detailing the FDA clearance. No specific guidance, risk factors, or contingencies are discussed within the body of this 8-K text.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the commercial launch timeline of the AtriClip Gillinov-Cosgrove system.
- Confirm the specific indications for use and any limitations associated with the FDA clearance.
- Review subsequent quarterly reports (10-Q) or annual reports (10-K) for financial impact analysis of this new product approval.